Gastrointestinal
The Rare Responsibility: Fueling the Journey
Dear Impossible Readers,
The gastrointestinal system is among the most intricate systems in the human body. It not only digests food and absorbs nutrients but also houses a significant portion of the immune system, coordinates complex networks of nerves and muscles, and acts as a barrier against the external environment. When problems arise, their effects can be wide-ranging. Rare gastrointestinal diseases can affect any part of this complex system and may result from various causes. Some are genetic or immune, while others result from infections, structural abnormalities, or nerve and muscle disorders within the digestive tract. Although each condition may affect only a small number of individuals, these diseases highlight the many ways the gastrointestinal system can malfunction.
The variety of rare gastrointestinal diseases becomes especially evident when examining specific cases. Very-early-onset inflammatory bowel disease, for instance, can result from genetic defects that impair immune function, causing severe intestinal inflammation at a very young age. Eosinophilic gastroenteritis is marked by an abnormal buildup of eosinophils, a type of immune cell, within the digestive tract. Intestinal lymphangiectasia, or Waldmann disease, has a structural cause, where abnormalities in the intestinal lymphatic vessels lead to leaks of proteins and other vital substances into the gut. Whipple’s disease stems from infection with the bacterium Tropheryma whipplei, while chronic intestinal pseudo-obstruction arises due to nerve or muscle issues that hinder the movement of contents through the digestive system.
Treatment varies with the cause. Immune-mediated conditions like early-onset inflammatory bowel disease and eosinophilic gastroenteritis may be treated with anti-inflammatory or immunosuppressive drugs, with some benefiting from targeted therapies. Intestinal lymphangiectasia is managed through diet and nutrition, while Whipple’s disease requires antibiotics. Chronic intestinal pseudo-obstruction might need motility medications and nutritional support, with severe cases needing intensive care. Treatments may target causes or focus on symptom control, complication prevention, and maintaining nutrition and quality of life.
The future of treatment will likely depend more on precision medicine, with improved genetic testing helping identify causes of some rare gastrointestinal diseases, especially those linked to immune system defects. This could enable treatments to go beyond managing inflammation or symptoms and target specific disease pathways. Biological therapies may more precisely influence immune activity, while advances in gene and cell treatments could offer new options for genetically defined conditions. Research into the microbiome, intestinal barrier, immune system, and neuromuscular control may also reveal new therapies. Ultimately, progress may come from understanding each condition’s specific mechanism.
Early diagnosis and access to specialised care are crucial for rare gastrointestinal diseases, which often mimic common disorders, leading to diagnosis delays. Increased awareness, better testing, specialist referral, nutritional support, and suitable treatments can make a big difference. These five diseases illustrate that rare gastrointestinal disorders are diverse, with unique causes, challenges, and treatment options. Recognising their differences is key to improving future care. Rare gastrointestinal diseases are increasingly moving from broad symptom management toward mechanism-based treatment.
Yours Possibly
Which rare disease category would you like me to cover next?
Further Reading
Abhari, A.P., Rezvanian, P., Sohrabi, E., Hosseini, K., Attauabi, M., Gupta, R. and Najafi, K., 2026. Targeted therapies and their outcomes in monogenic very early onset inflammatory bowel disease: a systematic review. BMC gastroenterology, 26(1), p.113.
Basilisco, G., Marchi, M. and Coletta, M., 2024. Chronic intestinal pseudo‐obstruction in adults: a practical guide to identify patient subgroups that are suitable for more specific treatments. Neurogastroenterology & Motility, 36(1), p.e14715.
Dalby, C., Shen, T., Thélin, C., Ganam, S., Velanovich, V. and Sujka, J., 2025. Surgical and therapeutic interventions for chronic intestinal pseudo-obstruction: a scoping review. Journal of Neurogastroenterology and Motility, 31(1), p.8.
Gonsalves, N., Doerfler, B., Zalewski, A., Yang, G.Y., Martin, L.J., Zhang, X., Shoda, T., Brusilovsky, M., Aceves, S., Thompson, K. and Spergel, A.K.R., 2023. Prospective study of an amino acid–based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. Journal of Allergy and Clinical Immunology, 152(3), pp.676-688.
Kliewer, K.L., Murray-Petzold, C., Collins, M.H., Abonia, J.P., Bolton, S.M., DiTommaso, L.A., Martin, L.J., Zhang, X., Mukkada, V.A., Putnam, P.E. and Kellner, E.S., 2023. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology & Hepatology, 8(9), pp.803-815.
Mansour, M.A., Malaeb, R.W., Elnemr, I.E., El-Salamoni, M.A.F., Mostafa, H.N. and Ahmadi, Z., 2025. Central nervous system involvement in Whipple’s disease: Report of a rare pathological entity and comparative review of treatment strategies and outcomes. Radiology Case Reports, 20(3), pp.1425-1430.
Nahid, K.L., Rukunuzzaman, M. and Fathema, K., 2024. Very Early Onset Inflammatory Bowel Disease (VEO-IBD): Diagnostic and Therapeutic Challenges for Pediatric Gastroenterologists. Mymensingh Med J, 33(3).
Vignes, S., Uzzan, M., Arrivé, L., Le Pimpec-Barthes, F., Fieschi, C., Lefèvre, G., Javalet, M., Bettolo, J. and Dubern, B., 2025. Primary intestinal lymphangiectasia: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins). Orphanet Journal of Rare Diseases, 20(1), p.356.